Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T36725 Target Info
Target Name Carboxypeptidase B1 (CPB1)
Synonyms Pancreas-specific protein; PASP; Carboxypeptidase B; CPB
Target Type Patented-recorded Target
Gene Name CPB1
Biochemical Class Peptidase
UniProt ID
CBPB1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US8710232
Title Imidazole derivatives used as TAFIa inhibitors
Abstract The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
Applicant(s) Sanofi-Aventis Deutschland GmbH
Representative Drug(s) D0YI7A Drug Info IC50 = 16 nM Click to Show More [1]
2 D01XTB Drug Info IC50 = 30 nM [1]
3 D01OFO Drug Info IC50 = 1130 nM [1]
Patent ID US8710232
Title Imidazole derivatives used as TAFIa inhibitors
Abstract The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
Applicant(s) Sanofi-Aventis Deutschland GmbH
Representative Drug(s) D0YI7A Drug Info IC50 = 16 nM Click to Show More [1]
2 D01XTB Drug Info IC50 = 30 nM [1]
3 D01OFO Drug Info IC50 = 1130 nM [1]
Patent ID US8710232
Title Imidazole derivatives used as TAFIa inhibitors
Abstract The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
Applicant(s) Sanofi-Aventis Deutschland GmbH
Representative Drug(s) D0YI7A Drug Info IC50 = 16 nM Click to Show More [1]
2 D01XTB Drug Info IC50 = 30 nM [1]
3 D01OFO Drug Info IC50 = 1130 nM [1]
References  Top
REF 1 Imidazole derivatives used as TAFIa inhibitors. US8710232.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.